当前位置：
X-MOL 学术
›
Jpn. J. Clin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma
Japanese Journal of Clinical Oncology ( IF 2.4 ) Pub Date : 2021-09-08 , DOI: 10.1093/jjco/hyab142 Hiroki Ishihara 1 , Tsunenori Kondo 1 , Kazutaka Nakamura 2 , Yuki Nemoto 3 , Hidekazu Tachibana 1, 4 , Hironori Fukuda 5 , Kazuhiko Yoshida 5 , Hirohito Kobayashi 1 , Junpei Iizuka 5 , Hiroaki Shimmura 2 , Yasunobu Hashimoto 3 , Kazunari Tanabe 5 , Toshio Takagi 5
Japanese Journal of Clinical Oncology ( IF 2.4 ) Pub Date : 2021-09-08 , DOI: 10.1093/jjco/hyab142 Hiroki Ishihara 1 , Tsunenori Kondo 1 , Kazutaka Nakamura 2 , Yuki Nemoto 3 , Hidekazu Tachibana 1, 4 , Hironori Fukuda 5 , Kazuhiko Yoshida 5 , Hirohito Kobayashi 1 , Junpei Iizuka 5 , Hiroaki Shimmura 2 , Yasunobu Hashimoto 3 , Kazunari Tanabe 5 , Toshio Takagi 5
Affiliation
To investigate the prognostic impact of tumor burden in patients receiving nivolumab plus ipilimumab as first-line therapy for previously untreated metastatic renal cell carcinoma (mRCC).
中文翻译：
肿瘤负荷与纳武单抗联合易普利姆玛治疗既往未治疗转移性肾细胞癌一线治疗结果的相关性
研究肿瘤负荷对接受纳武单抗联合易普利姆玛作为既往未治疗转移性肾细胞癌 (mRCC) 一线治疗的患者的预后影响。
更新日期：2021-09-08
中文翻译：
肿瘤负荷与纳武单抗联合易普利姆玛治疗既往未治疗转移性肾细胞癌一线治疗结果的相关性
研究肿瘤负荷对接受纳武单抗联合易普利姆玛作为既往未治疗转移性肾细胞癌 (mRCC) 一线治疗的患者的预后影响。
京公网安备 11010802027423号